Short and long-term effects of high-dose intravenous methylprednisolone pulse therapy on thyroid-associated ophthalmopathy

Liu,Xiaomei; Wang,Shu; Qin,Li; Qiang,Wei; Dahal,Mahesh; Fan,Ping; Gao,Shan; Shi,Bingyin

doi:10.3892/etm.2016.3446

Short and long-term effects of high-dose intravenous methylprednisolone pulse therapy on thyroid-associated ophthalmopathy

Authors:
- Xiaomei Liu
- Shu Wang
- Li Qin
- Wei Qiang
- Mahesh Dahal
- Ping Fan
- Shan Gao
- Bingyin Shi
View Affiliations

Affiliations: Department of Endocrinology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China, Department of Ophthalmology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China, Department of Rheumatism, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China, Department of Endocrinology, Shaanxi Provincial People's Hospital Affiliated to Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China
Published online on: June 9, 2016 https://doi.org/10.3892/etm.2016.3446
Pages: 901-908
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The majority of previous studies on high-dose intravenous methylprednisolone pulse (IVMP) therapy have observed the clinical conditions of patients prior to and following treatment without any long‑term follow‑up, and these studies have predominantly focused on combined treatment. The present prospective clinical study aimed to assess the long‑term effects and safety of high‑dose IVMP therapy in thyroid‑associated ophthalmopathy (TAO), as well as the significance of thyrotropin receptor antibody (TRAb) and soluble intercellular adhesion molecule‑l (sICAM‑1) during IVMP therapy. A total of 58 patients with TAO were treated with high‑dose IVMP therapy, and their clinical characteristics and indices were recorded before, during and after therapy, with a 12‑57 month (mean, 28.4 months) follow‑up. Before treatment and on the second day after each IVMP therapy, serum TRAb and sICAM‑1 levels were evaluated in 23 patients with TAO via a competitive radioimmunoassay and enzyme‑linked immunosorbent assay, respectively. The results of the present study demonstrated that the symptoms of eyelid swelling, ophthalmodynia, photophobia, lacrimation and diplopia, and visual acuity, ocular motility, proptosis and clinical activity score (CAS) indices were all significantly improved after IVMP therapy. In addition, analysis of covariance demonstrated that alterations in the levels of serum TRAb during the course of treatment were associated with CAS of TAO, whereas the change in serum sICAM‑1 was not. In conclusion, high‑dose IVMP therapy is an effective, safe, stable and well‑tolerated treatment for TAO, which is associated with rare, minor adverse effects. Furthermore, serum TRAb levels are correlated with the CAS of TAO and may serve as a predictor of the response to methylprednisolone therapy.

View Figures

View References

1	Wall JR and Lahooti H: Pathogenesis of thyroid eye disease - does autoimmunity against the TSH receptor explain all cases? Endokrynol Pol. 61:222–227. 2010.PubMed/NCBI
2	Bartley GB: The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Trans Am Ophthalmol Soc. 92:477–588. 1994.PubMed/NCBI
3	Brent GA: Clinical practice. Graves' disease. N Engl J Med. 358:2594–2605. 2008. View Article : Google Scholar : PubMed/NCBI
4	Kinsell LW, Partridge JW and Foreman N: The use of ACTH and cortisone in the treatment and in the differential diagnosis of malignant exophthalmos. Ann Intern Med. 38:913–917. 1953. View Article : Google Scholar : PubMed/NCBI
5	Bartalena L and Tanda ML: Clinical practice. Graves' ophthalmopathy. N Engl J Med. 360:994–1001. 2009. View Article : Google Scholar : PubMed/NCBI
6	Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C, Mourits M, Perros P, Boboridis K, Boschi A, Currò N, Daumerie C, Kahaly GJ, Krassas GE, Lane CM, Lazarus JH, Marinò M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx G and Wiersinga WM: European Group on Graves' Orbitopathy (EUGOGO). Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol. 158:273–285. 2008. View Article : Google Scholar : PubMed/NCBI
7	Khoo DH, Eng PH, Ho SC, Tai ES, Morgenthaler NG, Seah LL, Fong KS, Chee SP, Choo CT and Aw SE: Graves' ophthalmopathy in the absence of elevated free thyroxine and triiodothyronine levels: Prevalence, natural history and thyrotropin receptor antibody levels. Thyroid. 10:1093–1100. 2000. View Article : Google Scholar : PubMed/NCBI
8	Khoo DH, Ho SC, Seah LL, Fong KS, Tai ES, Chee SP, Eng PH, Aw SE and Fok AC: The combination of absent thyroid peroxidase antibodies and high thyroid-stimulating immunoglobulin levels in Graves' disease identifies a group at markedly increased risk of ophthalmopathy. Thyroid. 9:1175–1180. 1999. View Article : Google Scholar : PubMed/NCBI
9	De Bellis A, Di Martino S, Fiordelisi F, Muccitelli VI, Sinisi AA, Abbate GF, Gargano D, Bellastella A and Bizzarro A: Soluble intercellular adhesion molecule-1 (sICAM-1) concentrations in Graves' disease patients followed up for development of ophthalmopathy. J Clin Endocrinol Metab. 83:1222–1225. 1998. View Article : Google Scholar : PubMed/NCBI
10	Heufelder AE and Bahn RS: Soluble intercellular adhesion molecule-1 (sICAM-1) in sera of patients with Graves' ophthalmopathy and thyroid diseases. Clin Exp Immunol. 92:296–302. 1993. View Article : Google Scholar : PubMed/NCBI
11	Dickinson AJ and Perros P: Controversies in the clinical evaluation of active thyroid-associated orbitopathy: Use of a detailed protocol with comparative photographs for objective assessment. Clin Endocrinol (Oxf). 55:283–303. 2001. View Article : Google Scholar : PubMed/NCBI
12	Mourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A and van der Gaag R: Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: A novel approach. Br J Ophthalmol. 73:639–644. 1989. View Article : Google Scholar : PubMed/NCBI
13	Yang DD, Gonzalez MO and Durairaj VD: Medical management of thyroid eye disease. Saudi J Ophthalmol. 25:3–13. 2011. View Article : Google Scholar : PubMed/NCBI
14	Wakelkamp IM, Baldeschi L, Saeed P, Mourits MP, Prummel MF and Wiersinga WM: Surgical or medical decompression as a first-line treatment of optic neuropathy in Graves' ophthalmopathy? A randomized controlled trial. Clin Endocrinol (Oxf). 63:323–328. 2005. View Article : Google Scholar : PubMed/NCBI
15	Tambe K, Bhargava J, Tripathi A, Gregory M, Burns J and Sampath R: The role of intravenous methylprednisolone immunosuppression in the management of active thyroid eye disease. Orbit. 29:227–231. 2010. View Article : Google Scholar : PubMed/NCBI
16	Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C, Mourits M, Perros P, Boboridis K, Boschi A, et al: Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol. 158:273–285. 2008. View Article : Google Scholar : PubMed/NCBI
17	Zang S, Ponto KA and Kahaly GJ: Clinical review: Intravenous glucocorticoids for Graves' orbitopathy: Efficacy and morbidity. J Clin Endocrinol Metab. 96:320–332. 2011. View Article : Google Scholar : PubMed/NCBI
18	Chang TC, Kao SC, Hsiao YL, Lu CP, Huang KM and Tzeng SS: Therapeutic responses to corticosteroids in Graves' ophthalmopathy. J Formos Med Assoc. 95:833–838. 1996.PubMed/NCBI
19	Ohtsuka K, Sato A, Kawaguchi S, Hashimoto M and Suzuki Y: Effect of steroid pulse therapy with and without orbital radiotherapy on Graves' ophthalmopathy. Am J Ophthalmol. 135:285–290. 2003. View Article : Google Scholar : PubMed/NCBI
20	Sánchez-Orgaz M, Grabowska A, Royo-Oreja A, Asencio-Durán M, Romero-Martín R and Arbizu-Duralde A: Optic neuropathy following orbital irradiation for Graves' ophthalmopathy: A case report and literature review. Orbit. 31:30–33. 2012. View Article : Google Scholar : PubMed/NCBI
21	European Group of Graves' Orbitopathy. Perros P, Baldeschi L, Boboridis K, Dickinson AJ, Hullo A, Kahaly GJ, Kendall-Taylor P, Krassas GE, Lane CM, Lazarus JH, et al: A questionnaire survey on the management of Graves' orbitopathy in Europe. Eur J Endocrinol. 155:207–211. 2006. View Article : Google Scholar : PubMed/NCBI
22	Ramos HE, Diehl LA, Camacho CP, Perros P and Graf H: Latin American Thyroid Society: Management of Graves' orbitopathy in Latin America: An international questionnaire study compared with Europe. Clin Endocrinol (Oxf). 69:951–956. 2008. View Article : Google Scholar : PubMed/NCBI
23	Stiebel-Kalish H, Robenshtok E, Hasanreisoglu M, Ezrachi D, Shimon I and Leibovici L: Treatment modalities for Graves' ophthalmopathy: Systematic review and metaanalysis. J Clin Endocrinol Metab. 94:2708–2716. 2009. View Article : Google Scholar : PubMed/NCBI
24	Gillespie EF, Smith TJ and Douglas RS: Thyroid eye disease: Towards an evidence base for treatment in the 21st century. Curr Neurol Neurosci Rep. 12:318–324. 2012. View Article : Google Scholar : PubMed/NCBI
25	Hägg E and Asplund K: Is endocrine ophthalmopathy related to smoking? Br Med J (Clin Res Ed). 295:634–635. 1987. View Article : Google Scholar : PubMed/NCBI
26	Bartalena L, Martino E, Marcocci C, Bogazzi F, Panicucci M, Velluzzi F, Loviselli A and Pinchera A: More on smoking habits and Graves' ophthalmopathy. J Endocrinol Invest. 12:733–737. 1989. View Article : Google Scholar : PubMed/NCBI
27	Bahn RS: Graves' ophthalmopathy. N Engl J Med. 362:726–738. 2010. View Article : Google Scholar : PubMed/NCBI
28	Prummel MF and Wiersinga WM: Smoking and risk of Graves' disease. JAMA. 269:479–482. 1993. View Article : Google Scholar : PubMed/NCBI
29	Chen YL, Chang TC and Chen CJ: Influence of smoking on Graves' disease with or without ophthalmopathy and nontoxic nodular goiter in Taiwan. J Formos Med Assoc. 93:40–44. 1994.PubMed/NCBI
30	Briassoulis G, Papassotiriou I, Mavrikiou M, Lazaropoulou C and Margeli A: Longitudinal course and clinical significance of TGF-beta1, sL- and sE-Selectins and sICAM-1 levels during severe acute stress in children. Clin Biochem. 40:299–304. 2007. View Article : Google Scholar : PubMed/NCBI
31	Zhou SL, Chen YL, Peng XZ, Zhao YX, Xie PZ, Ling L, Chen XW and Dai KM: Expression of serum sICAM-1 in patients with primary hepatocellular carcinoma and its relationship with liver fibrosis. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 28:181–182. 2012.(In Chinese). PubMed/NCBI
32	de Pablo R, Monserrat J, Reyes E, Díaz D, Rodríguez-Zapata M, de la Hera A, Prieto A and Álvarez-Mon M: Circulating sICAM-1 and sE-Selectin as biomarker of infection and prognosis in patients with systemic inflammatory response syndrome. Eur J Intern Med. 24:132–138. 2013. View Article : Google Scholar : PubMed/NCBI
33	Cha JJ, Hyun YY, Jee YH, Lee MJ, Han KH, Kang YS, Han SY and Cha DR: Plasma concentration of soluble intercellular adhesion molecule-1 (sICAM-1) is elevated in type 2 diabetic patients, and sICAM-1 synthesis is associated with leptin-induced activation of the mitogen-activated protein kinase (MAPK) pathway. Inflammation. 36:878–887. 2013. View Article : Google Scholar : PubMed/NCBI
34	Dymicka-Piekarska V, Guzinska-Ustymowicz K, Kuklinski A and Kemona H: Prognostic significance of adhesion molecules (sICAM-1, sVCAM-1) and VEGF in colorectal cancer patients. Thromb Res. 129:e47–e50. 2012. View Article : Google Scholar : PubMed/NCBI